Apogee Therapeutics' Phase 2 Data Positions Zumilokibart (APG777) as Convenient Alternative to Dupixent and Ebglyss in Eczema Treatment

on

Apogee Therapeutics announced positive 52-week maintenance data from Phase 2 APEX Part A trial of zumilokibart (APG777) on March 23, 2026, showing durable response maintenance with every 3- and 6-month dosing in moderate-to-severe atopic dermatitis patients.1

Among Week 16 responders, 75% (3-month) and 85% (6-month) maintained EASI-75, with 86% and 78% achieving vIGA 0/1 respectively; deepening of response observed across all endpoints.1

APG777 offers significantly less frequent dosing than current standards like Dupixent (every 2-4 weeks) and Ebglyss (every 4 weeks), addressing injection burden and improving compliance.134

16-week induction data showed 71% EASI reduction, 66.9% EASI-75 (highest placebo-adjusted for any biologic), and rapid itch relief, with efficacy comparable to Dupixent and Ebglyss.234

Well-tolerated with safety profile consistent with class; Phase 2 Part B readout expected 2Q 2026, Phase 3 to start 2H 2026.1

Sources:

1. https://www.globenewswire.com/news-release/2026/03/23/3260201/0/en/Apogee-Therapeutics-Announces-Positive-Phase-2-Part-A-52-Week-Data-of-Zumilokibart-APG777-Demonstrating-Maintenance-and-Deepening-of-Responses-with-Every-3-and-6-Month-Dosing-in-Mo.html

2. https://www.hcplive.com/view/positive-16-week-findings-identified-apg777-patients-atopic-dermatitis

3. https://thedermdigest.com/ad-pipeline-watch-apogees-apg777-achieves-a-71-reduction-in-easi-scores-at-16-weeks/

4. https://www.statnews.com/2025/07/07/apogee-therapeutics-eczema-drug-study-results/